Slingshot members are tracking this event:

European Commission Adopts Positive Opinion Recommending Novartis' (NVS) Arzerra in Adults with Relapsed Chronic Lymphocytic Leukemia (CLL)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords European Commission, Chmp, Positive Opinion, Arzerra, Chronic Lymphocytic Leukemia, Cll